IRONWOOD PHARMACEUTICALS INCIRWDEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
Revenue
$122.1M
Gross Profit
N/A
Operating Profit
$75.5M
Net Profit
$40.1M
Gross Margin
N/A
Operating Margin
61.8%
Net Margin
32.8%
YoY Growth
33.3%
EPS
$0.23
IRONWOOD PHARMACEUTICALS INC Q3 FY2025 Financial Summary
IRONWOOD PHARMACEUTICALS INC reported revenue of $122.1M (up 33.3% YoY) for Q3 FY2025, with a net profit of $40.1M (up 999.3% YoY) (32.8% margin).
Key Financial Metrics
| Total Revenue | $122.1M |
|---|---|
| Net Profit | $40.1M |
| Gross Margin | N/A |
| Operating Margin | 61.8% |
| Report Period | Q3 FY2025 |
IRONWOOD PHARMACEUTICALS INC Annual Revenue by Year
IRONWOOD PHARMACEUTICALS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $296.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $296.2M |
| 2024 | $351.4M |
| 2023 | $442.7M |
| 2022 | $410.6M |
IRONWOOD PHARMACEUTICALS INC Quarterly Revenue & Net Profit History
IRONWOOD PHARMACEUTICALS INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $47.7M | -47.3% | $-2.3M | -4.8% |
| Q3 FY2025 | $122.1M | +33.3% | $40.1M | 32.8% |
| Q2 FY2025 | $85.2M | -9.7% | $23.6M | 27.7% |
| Q1 FY2025 | $41.1M | -45.1% | $-37.4M | -90.9% |
| Q4 FY2024 | $90.5M | -23.0% | $2.3M | 2.5% |
| Q3 FY2024 | $91.6M | -19.5% | $3.6M | 4.0% |
| Q2 FY2024 | $94.4M | -12.1% | $-860.0K | -0.9% |
| Q1 FY2024 | $74.9M | -28.0% | $-4.2M | -5.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $74.9M | $94.4M | $91.6M | $90.5M | $41.1M | $85.2M | $122.1M | $47.7M |
| YoY Growth | -28.0% | -12.1% | -19.5% | -23.0% | -45.1% | -9.7% | 33.3% | -47.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $438.8M | $395.6M | $389.5M | $350.9M | $327.2M | $342.9M | $396.1M | $396.9M |
| Liabilities | $769.3M | $717.3M | $700.9M | $652.2M | $661.3M | $651.1M | $660.2M | $658.7M |
| Equity | $-330.5M | $-321.7M | $-311.3M | $-301.3M | $-334.1M | $-308.2M | $-264.2M | $-261.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $45.0M | $33.5M | $9.9M | $15.2M | $20.0M | $-15.1M | $47.6M | $74.6M |